ADVM - Adverum Biotechnologies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Adverum Biotechnologies, Inc.

1035 O'Brien Drive
Suite A
Menlo Park, CA 94025
United States
650-272-6269
http://www.adverum.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees73

Key Executives

NameTitlePayExercisedYear Born
Ms. Leone D. PattersonCEO & Director807.91kN/A1963
Dr. Mehdi GasmiConsultant & Director589.81kN/A1967
Dr. Amber SalzmanConsultant564.31kN/A1962
Mr. Thomas LeungChief Financial OfficerN/AN/A1981
Ms. Myesha LacyVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, engages in developing gene therapy product candidates to treat ocular and rare diseases. Its pipeline of product candidates includes ADVM-022, an adeno- associated virus (AAV). 7m8-aflibercept for the treatment of wet age-related macular degeneration; ADVM-043, an investigational gene therapy candidate for the treatment of alpha-1 antitrypsin deficiency; and ADVM-053, a preclinical gene therapy product candidate for the treatment of hereditary angioedema. The company has collaboration agreements with Editas Medicine, Inc. to leverage its proprietary AAV vectors for genome editing technologies to treat up to five inherited retinal diseases; and Regeneron Pharmaceuticals, Inc. for the development of up to eight distinct ocular therapeutic targets. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.

Corporate Governance

Adverum Biotechnologies, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 10. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.